Collaboration Agreement - Additional Information (Details) - USD ($) $ in Millions		9 Months Ended
	May 31, 2021	Sep. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments receivable	$ 135.0
Deferred Revenue		$ 8.3
Deferred Revenue Related to Development Activites		3.7
Clinical Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 12.0
Upfront payment recognition in future periods to settlement of obligation		$ 12.0
Deferred revenue, description		Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations. The potential milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.